BBIO
BridgeBio Pharma, Inc. NASDAQ$68.99
Mkt Cap $13.4B
52w Low $31.77
70.0% of range
52w High $84.94
50d MA $71.18
200d MA $64.39
P/E (TTM)
-18.1x
EV/EBITDA
-25.6x
P/B
—
Debt/Equity
-1.3x
ROE
35.1%
P/FCF
-33.8x
RSI (14)
—
ATR (14)
—
Beta
1.09
50d MA
$71.18
200d MA
$64.39
Avg Volume
2.7M
About
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clini…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.71 | -1.00 | -40.2% | 68.31 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% | — |
| Oct 29, 2025 | AMC | -0.88 | -0.95 | -8.0% | 66.62 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% | — |
| Aug 5, 2025 | AMC | -0.83 | -0.95 | -14.5% | 49.21 | -9.6% | -8.9% | -6.6% | -5.3% | -2.0% | -0.2% | — |
| Apr 29, 2025 | AMC | -1.00 | -0.88 | +12.0% | 36.42 | +6.0% | +5.3% | +5.4% | +5.9% | +4.9% | +1.4% | — |
| Feb 20, 2025 | AMC | -1.09 | -1.31 | -20.2% | 36.81 | +3.1% | +0.1% | -1.5% | -6.7% | -9.1% | -7.0% | — |
| Nov 12, 2024 | AMC | -1.03 | -0.86 | +16.5% | 24.62 | +1.2% | +0.7% | -2.1% | -3.7% | -9.2% | -8.4% | — |
| Aug 1, 2024 | AMC | -1.09 | -1.02 | +6.4% | 26.18 | -6.6% | +0.0% | -2.6% | -5.0% | -8.6% | -6.5% | — |
| May 2, 2024 | AMC | -0.40 | -0.05 | +87.5% | 27.74 | +2.6% | +0.3% | +1.3% | +0.2% | -0.1% | +3.6% | — |
| Feb 22, 2024 | AMC | -0.95 | -0.96 | -1.1% | 33.60 | +2.2% | +1.2% | +3.8% | +6.3% | +5.0% | +1.6% | — |
| Nov 2, 2023 | AMC | -0.86 | -1.08 | -25.6% | 26.92 | +2.4% | +7.1% | +3.6% | +9.2% | +9.2% | +0.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Truist | Maintains | Buy → Buy | — | $69.71 | $68.35 | -2.0% | +1.8% | +2.0% | -1.6% | — | — |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.71 | $68.35 | -2.0% | +1.8% | +2.0% | -1.6% | — | — |
| Apr 28 | Mizuho | Maintains | Outperform → Outperform | — | $74.52 | $83.20 | +11.6% | -6.5% | -4.8% | -4.6% | -8.0% | — |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.28 | $75.86 | +3.5% | +1.7% | -4.9% | -3.2% | -3.0% | -6.4% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $70.94 | $70.94 | +0.0% | -1.2% | -1.2% | -3.4% | -1.9% | -3.4% |
| Mar 10 | JP Morgan | Maintains | Overweight → Overweight | — | $65.64 | $66.12 | +0.7% | +13.2% | +8.8% | +3.6% | +5.7% | +8.2% |
| Feb 25 | Truist | Maintains | Buy → Buy | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
Recent Filings
8-K · 7.01
! Medium
BridgeBio Oncology Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
BridgeBio Oncology announced leadership transitions on April 22, 2026, which could signal strategic shifts affecting company direction and investor confidence.
Apr 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BridgeBio's positive Phase 3 data for BBP-418 and anticipated FDA approval in late 2026/early 2027 could validate a potentially first-in-class rare disease treatment, significantly boosting revenue growth if commercialization succeeds.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kumar's departure as CEO of BridgeBio Oncology signals potential leadership instability at the oncology subsidiary, which could impact clinical trial progress and investor confidence in the parent company's pipeline.
Mar 25
8-K
BridgeBio Pharma, Inc. -- 8-K Filing
BridgeBio plans to submit an NDA for encaleret in late 2025/early 2026 following positive Phase 3 results, targeting a market launch in late 2026 or early 2027.
Feb 24
8-K · 8.01
!! High
BridgeBio Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
BridgeBio Pharma's infigratinib achieved statistical significance in Phase 3 achondroplasia trials for body proportionality improvements, potentially supporting a future regulatory submission for this genetic disorder treatment.
Feb 12
Data updated apr 24, 2026 8:42pm
· Source: massive.com